Answers are grounded in this paper and cite their sources.
Prostate-specific membrane antigen (PSMA)-targeted PET imaging plays a well-established role in staging, detecting recurrence, and selecting patients for PSMA-targeted radiopharmaceutical therapy in prostate cancer. We present a case of PSMA-expressing recurrent prostate cancer in the pelvis, involving the urinary bladder wall and pelvic lymph nodes that was not completely visualized on 18 F-DCFPyL PET/CT, but clearly delineated on 18 F-rhPSMA-7.3 PET/CT. This discrepancy is attributed to the significantly lower urinary excretion and consequent low urinary bladder activity with 18 F-rhPSMA, yielding high target-to-background ratios in the pelvis, and highlighting its potential diagnostic advantage in evaluating pelvic lesions near the urinary bladder.
No takes yet. Share an insight, caveat, or question.
Jindal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: